22 May 2013
Keywords: xoma, starts, second, neuprex, efficacy, trial, received
Article | 05 June 1995
Xoma has received US Food and Drug Administration approval to begin its
second Phase III efficacy trial of Neuprex (recombinant ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 June 1995
29 May 1995
21 May 2013
© 2013 thepharmaletter.com